tiprankstipranks
Trending News
More News >
Surrozen, Inc. (SRZN)
:SRZN
US Market
Advertisement

Surrozen (SRZN) Stock Forecast & Price Target

Compare
38 Followers
See the Price Targets and Ratings of:

SRZN Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Surrozen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SRZN Stock 12 Month Forecast

Average Price Target

$37.00
▲(270.74% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Surrozen in the last 3 months. The average price target is $37.00 with a high forecast of $42.00 and a low forecast of $32.00. The average price target represents a 270.74% change from the last price of $9.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","26":"$26","43":"$43","17.5":"$17.5","34.5":"$34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,17.5,26,34.5,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2022","6":"Mar<br/>2023","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11,13.384615384615385,15.76923076923077,18.153846153846153,20.53846153846154,22.923076923076923,25.307692307692307,27.692307692307693,30.076923076923077,32.46153846153846,34.84615384615385,37.230769230769226,39.61538461538461,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11,13,15,17,19,21,23,25,27,29,31,33,35,{"y":37,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11,12.615384615384615,14.23076923076923,15.846153846153847,17.46153846153846,19.076923076923077,20.692307692307693,22.307692307692307,23.923076923076923,25.53846153846154,27.153846153846153,28.76923076923077,30.384615384615387,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.5,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.5,"date":1630454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1633046400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1667260800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1677628800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.12,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$42.00Average Price Target$37.00Lowest Price Target$32.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SRZN
H.C. Wainwright
H.C. Wainwright
$32
Buy
220.64%
Upside
Reiterated
08/11/25
Surrozen's Innovative Wnt Pathway Approach Garners Buy Rating Amid Promising Preclinical DataValuation and Risks. We reiterate our Buy rating and $32 price target. Our price target of $32 per share is based on an equally- weighted composite of: (a) $47.98 per share, as a 25x multiple of taxed and diluted 2036 EPS of $7.36 discounted back to and (b) an NPV discounted cash flow between 2025-2036 of $15.78 per share, with a discount rate of 13% and growth rate of 1%. These assumptions are in-line with the expected P/E multiple and discount rates of a developmental- stage biopharmaceutical company.
Guggenheim Analyst forecast on SRZN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$42
Buy
320.84%
Upside
Reiterated
08/11/25
Guggenheim Keeps Their Buy Rating on Surrozen (SRZN)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on SRZN
H.C. Wainwright
H.C. Wainwright
$32
Buy
220.64%
Upside
Reiterated
08/11/25
Surrozen's Innovative Wnt Pathway Approach Garners Buy Rating Amid Promising Preclinical DataValuation and Risks. We reiterate our Buy rating and $32 price target. Our price target of $32 per share is based on an equally- weighted composite of: (a) $47.98 per share, as a 25x multiple of taxed and diluted 2036 EPS of $7.36 discounted back to and (b) an NPV discounted cash flow between 2025-2036 of $15.78 per share, with a discount rate of 13% and growth rate of 1%. These assumptions are in-line with the expected P/E multiple and discount rates of a developmental- stage biopharmaceutical company.
Guggenheim Analyst forecast on SRZN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$42
Buy
320.84%
Upside
Reiterated
08/11/25
Guggenheim Keeps Their Buy Rating on Surrozen (SRZN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Surrozen

1 Month
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
+1.70%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 25.00% of your transactions generating a profit, with an average return of +1.70% per trade.
3 Months
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-1.15%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -1.15% per trade.
1 Year
Matthew CaufieldH.C. Wainwright
Success Rate
1/4 ratings generated profit
25%
Average Return
-0.65%
reiterated a buy rating 3 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -0.65% per trade.
2 Years
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-0.65%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -0.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRZN Analyst Recommendation Trends

Rating
Nov 24
Jan 25
Apr 25
May 25
Aug 25
Strong Buy
2
3
3
4
4
Buy
0
0
0
0
0
Hold
0
2
4
4
2
Sell
3
3
4
1
1
Strong Sell
0
0
0
0
0
total
5
8
11
9
7
In the current month, SRZN has received 4 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. SRZN average Analyst price target in the past 3 months is 37.00.
Each month's total comprises the sum of three months' worth of ratings.

SRZN Financial Forecast

SRZN Earnings Forecast

Next quarter’s earnings estimate for SRZN is -$1.14 with a range of -$1.17 to -$1.10. The previous quarter’s EPS was $2.55. SRZN beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.34% of the time in the same period. In the last calendar year SRZN has Outperformed its overall industry.
Next quarter’s earnings estimate for SRZN is -$1.14 with a range of -$1.17 to -$1.10. The previous quarter’s EPS was $2.55. SRZN beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.34% of the time in the same period. In the last calendar year SRZN has Outperformed its overall industry.

SRZN Sales Forecast

Next quarter’s sales forecast for SRZN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $983.00K. SRZN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.72% of the time in the same period. In the last calendar year SRZN has Outperformed its overall industry.
Next quarter’s sales forecast for SRZN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $983.00K. SRZN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.72% of the time in the same period. In the last calendar year SRZN has Outperformed its overall industry.

SRZN Stock Forecast FAQ

What is SRZN’s average 12-month price target, according to analysts?
Based on analyst ratings, Surrozen, Inc.’s 12-month average price target is 37.00.
    What is SRZN’s upside potential, based on the analysts’ average price target?
    Surrozen, Inc. has 270.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SRZN a Buy, Sell or Hold?
          Surrozen, Inc. has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Surrozen, Inc.’s price target?
            The average price target for Surrozen, Inc. is 37.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $42.00 ,the lowest forecast is $32.00. The average price target represents 270.74% Increase from the current price of $9.98.
              What do analysts say about Surrozen, Inc.?
              Surrozen, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of SRZN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis